EDITORIAL article
Front. Pharmacol.
Sec. Obstetric and Pediatric Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1671327
This article is part of the Research TopicWorld Breastfeeding Week 2024: An Obstetric and Pediatric Pharmacology PerspectiveView all 8 articles
Editorial: World Breastfeeding Week 2024: an Obstetric and Pediatric Pharmacology Perspective
Provisionally accepted- 1University of Nottingham School of Life Sciences, Nottingham, United Kingdom
- 2Certara UK Limited, Sheffield, United Kingdom
- 3University of California San Diego, La Jolla, United States
- 4Department of Development and Regeneration, Faculty of Medicine, KU Leuven, Leuven, Belgium
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
World breastfeeding Week (WBW) is celebrated annually in the first week of August, organized by the World Alliance for Breastfeeding Action (WABA) the World Health Organization (WHO), and United Nations International Children's Emergency Fund (UNICEF), aiming to promote breastfeeding and its many benefits to mother and child (1,2). WHO recommends exclusive breastfeeding for the first six months of life, and if possible, continuing with supplemented breastfeeding for a further 1-2 years. These initiatives have significantly improved breastfeeding practices (1,2). Over the last 3 decades, death rates and disability-adjusted life years due to suboptimal breastfeeding reduced by approximately 80%, reflecting its relevant health benefit (3). Unfortunately, while the rates are increasing, WHO recommendations such as exclusive breastfeeding in the first six months are still only very partially attained. To raise the exclusive breastfeeding rate towards the WHO goals (achieving 70% exclusive breastfeeding at 6 months by 2030), targeted interventions are needed whereby participation of each stakeholder is crucial (1,4).Achieving this goal will require a better understanding of regional socio-economic drivers to develop tailored interventions, as well as the shared obligation to generate knowledge on pharmacotherapy and its safety during breastfeeding (4,5). There is still a huge information gap ('information desert') on medication safety during breastfeeding; even though most women require at least one medicine postpartum, in part due to a rising number in chronic diseases and pregnancies at later age (6,7).The goal of this research topic is to bring to the forefront critical research on breastfeeding from an obstetric and pediatric perspective, exploring a range of research strategies, involving in vitro, in vivo or computational techniques to address drug-related challenges associated with breastfeeding. We 35 intended to present diverse perspectives and encouraging interdisciplinary collaboration deepen 36 understanding of the implications of use during lactation on both mother and child. This special topic has limitations on its diversity of topics since e.g. bio-analysis, data analysis 92 incorporating maternal medical conditions, or ethics are not present. However, based on the newly 93 reported information on how to improve computational techniques, on DRPs in lactating women, and 94 on drug-specific or generic approaches to assess safety of drug exposure during lactation contributes 95 to this overarching aim to convert the 'information desert' into a more sustainable environment for all 96 stakeholders involved. 97
Keywords: Breastfeeding, lactation, Clinical Pharmacology, lactation related drug exposure, Safety, Modelling and simulation, Regulatory
Received: 22 Jul 2025; Accepted: 30 Jul 2025.
Copyright: © 2025 Olafuyi, Pansari, Anderson and Allegaert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Karel Allegaert, Department of Development and Regeneration, Faculty of Medicine, KU Leuven, Leuven, Belgium
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.